No Data
No Data
News On Intra-Cellular Therapies Inc. (ITCI) Now Under JNJ
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Express News | Cantor Fitzgerald Reiterates Neutral on Intra-Cellular Therapies, Maintains $132 Price Target
Intra-Cellular Therapies Analyst Ratings
Daily short sale tracking: Intra-Cellular Therapies's short volume increased by 6 million, with a short sale ratio of 46%
Johnson & Johnson Closes Intra-Cellular Therapies Acquisition; Expects Deal To Dilute Adj EPS By ~$0.25 in 2025
Benson_188 : moomoo 2025 Spring Festival red envelope! Test your luck and win up to 888* >> https://j.moomoo.com/023qve
CNNT : Enjoy reading about these stocks that are not on hype-seeking investors' radar. TQ.